Presentation is loading. Please wait.

Presentation is loading. Please wait.

Immune Checkpoint Inhibitors in Lung Cancer

Similar presentations


Presentation on theme: "Immune Checkpoint Inhibitors in Lung Cancer"— Presentation transcript:

1 Immune Checkpoint Inhibitors in Lung Cancer

2

3 This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. Data that we discuss should be considered preliminary until published in a peer-reviewed journal.

4 Currently Approved Checkpoint Inhibitors for Lung Cancer

5 Standard of Care for NSCLC

6 PD-L1 Testing Core Biopsy vs FNA

7 KEYNOTE-189 Efficacy

8 Choosing Between Monotherapy vs Combination Immunotherapy in PD-L1 High Expressers

9 KEYNOTE-042 Efficacy and Safety

10 Was KEYNOTE-042 Practice Changing?

11 TMB Assessment

12 CheckMate 227 Efficacy

13 CheckMate 227 PD-L1 Subgroups and Safety

14 KEYNOTE-407 Efficacy and Safety

15 IMpower131 Efficacy and Safety

16 EGFR-Mutant NSCLC

17 IMpower150 Efficacy

18 Treatment of EGFR-Mutant NSCLC Faculty Discussion

19 PACIFIC Updated Efficacy and Safety

20 ALCHEMIST Immunotherapy Trial

21 Mesothelioma Emerging Therapies

22 Second- and Third-Line Treatment of SCLC

23 IMpower133 Efficacy and Safety

24 Managing SCLC Faculty Recommendations

25 Overview of irAEs

26 Concluding Remarks

27 Abbreviations

28 Abbreviations (cont)

29 Abbreviations (cont)


Download ppt "Immune Checkpoint Inhibitors in Lung Cancer"

Similar presentations


Ads by Google